Sanofi (NYSE:SNY) announced today that it is planning to tender an offer to acquire all outstanding common stock shares of clinical-stage biotech company Synthorx. The agreement and plan of merger between the two companies was announced on Dec. 7 and the offer is being made pursuant to that. Sanofi said it stands to acquire the common […]
GE Healthcare, Fujifilm team up with Harvard, MIT on new $50m biotech center
GE Healthcare (NYSE:GE) and Fujifilm (TSE:4901) are entering into a partnership with Harvard University and Massachusetts Institute of Technology to establish a new $50 million center for advanced biological manufacturing and engineering. Harvard, MIT, GE Healthcare and Fujifilm are slated to comprise the center’s board of directors, along with Alexandria Real Estate Equities. Beth Israel Deaconess Medical […]
GenapSys secures $90 million in bid to upend sequencing
Following the raising of a $90 million Series C, privately held GenapSys will begin rolling out a line of low cost electronic-based genetic sequencing machines that it says could upend the research and clinical testing industries. CEO Hesaam Esfandyarpour says the Redwood City, Calif.–based company’s Sequencer, a table-top device that carries a price tag that’s […]
Skyline Medical to take 20% stake in Helomics, license Illumina’s gene sequencing tech
Fresh from its purchase of a 20% stake in joint venture partner Helomics, Skyline Medical (NSDQ:SKLN) said today that it inked a deal to license the MiSeqDx next-generation sequencing technology from Illumina (NSDQ:ILMN). Yesterday Minneapolis-based Skyline said it agreed to buy a lump of convertible shares representing 20% of Helomics, in exchange for 1.1 million newly issued SKLN shares, which […]
MedGenome raises $30m for biomarker discovery program
Genomics research and diagnostics company MedGenome said today that it closed a $30 million Series C round led by Sequoia India and Sofina. Zodius Capital, the co-founder & former CEO of Infosys, Kris Gopalakrishnan, and former Cognizant CEO Lakshmi Narayanan also participated in the round. The Foster City, Calif.-based company said it plans to use […]
Philips, Illumina to launch precision medicine cancer program with Navican
Royal Philips (NYSE:PHG) and Intermountain Healthcare company Navican inked an agreement today to launch a precision health informatics solution aimed at improving outcomes for late stage cancer patients. The program is slated to leverage Navican‘s TheraMap Precision Cancer Care services and Philips’ IntelliSpace Genomics platform, which uses Illumina‘s next-gen genomic sequencing technologies. At Utah-based Intermountain Healthcare’s […]
23andMe is back: FDA allows marketing of genetic health risk tests
FDA this month allowed genetic testing company 23andMe to market genetic health risk tests for 10 diseases and conditions including Parkinson’s disease and late-onset Alzheimer’s disease. The de novo premarket review authorization, announced April 6, also included celiac disease, which results in the inability to digest gluten; alpha-1 antitrypsin deficiency, which raises the risk of […]
Illumina, Novogene ink development deal for next-gen sequencing tech
Illumina (NSDQ:ILMN) and genomic service company Novogene said today they entered into an agreement to jointly develop advanced clinical applications for reproductive health and oncology based on next-generation sequencing technology. The collaboration will focus on providing advanced, integrated sequencing solutions to the clinical market, the company said. The 2 companies are slated to work together to create […]
Medtronic says a pair of studies show genetic link to sudden cardiac death
Medtronic (NYSE:MDT) today said 1st-of-a-kind results from a pair of independent clinical trials discovered a gene linked to abnormal heart rhythms that can lead to sudden cardiac death. Fridley, Minn.-based Medtronic said the studies, Discovery and Oregon SUDS, found a gene associated with SCD in patients with implantable cardioverter defibrillators. Results were presented over the weekend […]
PDI rejects Digirad buyout offer, buys RedPath instead
PDI has bought RedPath Integrated Pathology just days after rejecting a tentative buyout offer from Digirad Corp. (NSDQ:DRAD).
BD buys Irish next-gen sequencing startup GenCell Biosystems
- 1
- 2
- 3
- …
- 15
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube